This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/projekt/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F14%3A00073663%21RIV15-MSM-14110___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n18http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F14%3A00073663%21RIV15-MSM-14110___
rdf:type
n16:Vysledek skos:Concept
dcterms:description
Imatinib mesylate is a standard first-line therapy for patients with chronic myelogenous leukemia. However, there is still a significant proportion of these patients who reflect sub-optimal responses or fail imatinib therapy. Knowledge of the distribution within the studied system (e.g., peripheral blood) may be of high importance for understanding the principles of drug action and possible patient resistance to treatment. Intracellular or more precisely cell-associated, imatinib concentrations in patients, were shown to be higher compared to those in plasma, but still only limited data related to the methodology aspects of cell-associated concentrations are available. Herein is presented an assessment of the cell-associated imatinib determination assay by mass spectrometry. Three approaches were evaluated to isolate cells from the peripheral blood of chronic myelogenous leukemia patients. Erythrocyte lysis was found to cause substantial leakage of cell-associated imatinib in the first step. Imatinib mesylate is a standard first-line therapy for patients with chronic myelogenous leukemia. However, there is still a significant proportion of these patients who reflect sub-optimal responses or fail imatinib therapy. Knowledge of the distribution within the studied system (e.g., peripheral blood) may be of high importance for understanding the principles of drug action and possible patient resistance to treatment. Intracellular or more precisely cell-associated, imatinib concentrations in patients, were shown to be higher compared to those in plasma, but still only limited data related to the methodology aspects of cell-associated concentrations are available. Herein is presented an assessment of the cell-associated imatinib determination assay by mass spectrometry. Three approaches were evaluated to isolate cells from the peripheral blood of chronic myelogenous leukemia patients. Erythrocyte lysis was found to cause substantial leakage of cell-associated imatinib in the first step.
dcterms:title
Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry
skos:prefLabel
Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry
skos:notation
RIV/00216224:14110/14:00073663!RIV15-MSM-14110___
n3:aktivita
n5:P
n3:aktivity
P(ED1.1.00/02.0068), P(GBP206/12/G151), P(GBP302/12/G157)
n3:cisloPeriodika
6
n3:dodaniDat
n18:2015
n3:domaciTvurceVysledku
n4:6563902 n4:4376285 n4:9323023 n4:5378605 n4:2346257 n4:8054142 n4:3715434 n4:4568567 n4:4748891
n3:druhVysledku
n6:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
10779
n3:idVysledku
RIV/00216224:14110/14:00073663
n3:jazykVysledku
n7:eng
n3:klicovaSlova
Mass spectrometry; Flow cytometry; Cell isolation technique; Chronic myelogenous leukemia; Imatinib; Peripheral blood
n3:klicoveSlovo
n9:Imatinib n9:Mass%20spectrometry n9:Chronic%20myelogenous%20leukemia n9:Flow%20cytometry n9:Cell%20isolation%20technique n9:Peripheral%20blood
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[11637BC30216]
n3:nazevZdroje
Analytical Letters
n3:obor
n12:CB
n3:pocetDomacichTvurcuVysledku
9
n3:pocetTvurcuVysledku
11
n3:projekt
n10:GBP206%2F12%2FG151 n10:ED1.1.00%2F02.0068 n10:GBP302%2F12%2FG157
n3:rokUplatneniVysledku
n18:2014
n3:svazekPeriodika
47
n3:tvurceVysledku
Havelková, Martina Mayer, Jiří Ráčil, Zdeněk Šimara, Pavel Stejskal, Stanislav Krontorád Koutná, Irena Zdráhal, Zbyněk Rázga, Filip Potěšil, David Borský, Marek Dvořáková, Dana
n3:wos
000334070900005
s:issn
0003-2719
s:numberOfPages
14
n17:doi
10.1080/00032719.2013.860538
n15:organizacniJednotka
14110